T
Tim Maughan
Researcher at University of Oxford
Publications - 308
Citations - 14411
Tim Maughan is an academic researcher from University of Oxford. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 49, co-authored 276 publications receiving 11731 citations. Previous affiliations of Tim Maughan include Cardiff University & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem,Andrés Cervantes,René Adam,Alberto Sobrero,J.H.J.M. van Krieken,Dan Aderka,E. Aranda Aguilar,Alberto Bardelli,Al B. Benson,György Bodoky,Fortunato Ciardiello,André D'Hoore,Eduardo Díaz-Rubio,J.-Y. Douillard,Michel Ducreux,Alfredo Falcone,Axel Grothey,Thomas Gruenberger,Karin Haustermans,Volker Heinemann,Paulo M. Hoff,C.-H. Köhne,R. Labianca,Pierre Laurent-Puig,Brigette B.Y. Ma,Tim Maughan,Kei Muro,Nicola Normanno,Pia Österlund,Pia Österlund,Wim J.G. Oyen,Demetris Papamichael,George Pentheroudakis,Per Pfeiffer,Timothy J. Price,C.J.A. Punt,Jens Ricke,Arnaud Roth,R. Salazar,Werner Scheithauer,H.-J. Schmoll,Josep Tabernero,Julien Taieb,Sabine Tejpar,Harpreet Wasan,Takayuki Yoshino,Aziz Zaanan,Dirk Arnold +47 more
TL;DR: These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.
Journal ArticleDOI
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
Roger D James,Rob Glynne-Jones,Helen Meadows,David Cunningham,Arthur Sun Myint,Mark P Saunders,Tim Maughan,Alec McDonald,Sharadah Essapen,Martin Leslie,Stephen Falk,Charles Wilson,Simon Gollins,Rubina Begum,Jonathan A. Ledermann,Latha Kadalayil,David Sebag-Montefiore +16 more
TL;DR: The results of this trial--the largest in anal cancer to date--show that fluorouracil and mitomycin with 50.4 Gy radiotherapy in 28 daily fractions should remain standard practice in the UK.
Journal ArticleDOI
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
Matthew T. Seymour,Tim Maughan,Jonathan A. Ledermann,C. Topham,Roger D James,Stephen J. Gwyther,David Smith,Stephen F Shepherd,Anthony Maraveyas,D. R. Ferry,A Meade,L.C. Thompson,Gareth Griffiths,Mahesh K. B. Parmar,Richard Stephens +14 more
TL;DR: The data challenge the assumption that, in this non-curative setting, maximum tolerable treatment must necessarily be used first-line in patients with advanced colorectal cancer, and suggest the staged approach of initial single-agent treatment upgraded to combination when required is not worse than first- line combination.
Journal ArticleDOI
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch,Iris D. Nagtegaal,Tim Maughan,Christopher Smith,Jeremy Peter Cheadle,David Fisher,Richard Kaplan,Philip Quirke,Matthew T. Seymour,Susan D. Richman,Gerrit A. Meijer,Bauke Ylstra,Daniëlle A.M. Heideman,Anton F.J. de Haan,Cornelis J. A. Punt,Miriam Koopman +15 more
TL;DR: The data suggest that the poor prognosis of dMMR is driven by the BRAFMT status, and both biomarkers confer an inferior prognosis.
Journal ArticleDOI
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Jan Franko,Qian Shi,Jeffrey P. Meyers,Tim Maughan,Richard Adams,Matthew T. Seymour,Leonard B. Saltz,Cornelis J. A. Punt,Miriam Koopman,Christophe Tournigand,Niall C. Tebbutt,Eduardo Díaz-Rubio,John Souglakos,Alfredo Falcone,Benoist Chibaudel,Volker Heinemann,Joseph Moen,Aimery de Gramont,Daniel J. Sargent,Axel Grothey +19 more
TL;DR: The effect of the number and location of metastases in patients receiving first-line systemic chemotherapy is investigated to assess the prognostic associations of peritoneal metastatic colorectal cancer with overall survival and progression-free survival.